Sanofi (SNY) announced the immediate adoption of influenza strains selected by the Food and Drug Administration to advance the manufacturing ...

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target of €114.00. The company’s shares closed yesterday ...

Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

Sanofi India Limited, (Previously known as Aventis Pharma Limited ... In May 2007, the company launched a line extension, Amaryl M. A new granulation train dedicated for production of Combiflam ...

Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market. South Africa’s Competition ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Sanofi estimates that the annual cost for a typical patient will be around $280,000 per year before discounts or rebates, in line with other drugs used to treat rare, chronic diseases.

Also Read: Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study As a rapid-acting insulin, Merilog helps lower mealtime blood sugar spikes and improve blood ...

TEVA), and Sanofi today presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug (TEV’574/SAR447189), a human IgG1-λ2 monoclonal antibody targeting TL1A, for the ...

In the meantime, banks face an agonizing few months at the mercy of macroeconomic surprises and changeable markets. Representatives at CD&R, Citigroup, Goldman Sachs and Morgan Stanley declined to ...